Advances in rare disease treatments and clinical trial tools demand new regulatory frameworks, former commissioners say at a USC Schaeffer Center conference.
Advances in rare disease treatments and clinical trial tools demand new regulatory frameworks, former commissioners say at a USC Schaeffer Center conference.